Press releases
2 February 2022, Potsdam

AnalytiCon Discovery and Pharvaris extend their collaboration

AnalytiCon Discovery, a first-class provider of natural product, drug discovery and development services, today announced the extension of their research and development collaboration with Pharvaris, a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonist small molecules to patients.

AnalytiCon Discovery, a leader in the design and development of chiral compound libraries, has earned a strong reputation over the years as a drug discovery CRO in a wide range of collaborations. A key success story comes from its partnership with Pharvaris, a clinical-stage company specializing in the development of bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications.

Pharvaris has initiated Phase 2 studies of a bradykinin-B2-receptor antagonist for both on-demand and prophylactic treatment of HAE. With the extension of this collaboration for an additional 18 months, AnalytiCon Discovery and Pharvaris will continue to work together on the research and development of new bradykinin-B2-receptor antagonists to treat HAE and other conditions.

Jochen Knolle, Ph.D., chief scientific officer of Pharvaris, states: “We are thrilled that our collaboration with AnalytiCon Discovery has been extended. They have been our research partner from Pharvaris‘ inception and will continue to be instrumental in our drug discovery efforts on the development of new bradykinin-B2-receptor antagonists with the potential to treat additional indications.”

Christoph Gibson, Vice President Drug Discovery and Development at AnalytiCon Discovery, says: "We are pleased to extend our fruitful collaboration with Pharvaris focussing on the characterization and development of new bradykinin-B2-receptor antagonists. This will open up new therapeutic indications for this highly attractive drug target."

Lutz Müller-Kuhrt, chief executive officer of AnalytiCon Discovery, adds: "The collaboration between AnalytiCon Discovery and Pharvaris is an excellent example of a synergistic partnership between early-stage drug discovery and development experts to advance therapies efficiently in clinical development.”

Über AnalytiCon

AnalytiCon Discovery provides drug discovery and development services. The technology platform builds on an extensive reservoir of synthetic and natural compounds and is complemented by a first-class drug discovery and development team. AnalytiCon’s expertise also includes the identifica-tion and development of novel ingredients for the cosmetic and food industries. AnalytiCon has been a member of the BRAIN Group since 2013. Further information: www.ac-discovery.com

Contact

AnalytiCon Discovery GmbH
Dr. Lars Ole Haustedt
Vice President / Projects and Innovation
Phone: +49 175 560 2427
Email: l.haustedt@ac-discovery.com

AnalytiCon Discovery, LLC (USA)
Dr. Dietmar Wolf
Chief Business Officer
Phone: +1 240654 7575
Email: d.wolf@ac-discovery.com



About BRAIN

BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products – BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success.

BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.

Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page